An open-label pilot study of alefacept for the treatment of pyoderma gangrenosum

Journal of the European Academy of Dermatology and Venereology

Volumn 22, Issue 8, 2008, Pages 943-949

  Foss, C E ^a   Clark, A R ^a   Inabinet, R ^a   Camacho, F ^a   Jorizzo, J L ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Alefacept; Inflammation; Pyoderma gangrenosum; Treatment

Indexed keywords

ALEFACEPT;

ADULT; ARTICLE; CASE REPORT; CELL POPULATION; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PYODERMA GANGRENOSUM; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION;

DERMATOLOGIC AGENTS; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MODELS, STATISTICAL; PILOT PROJECTS; PROSPECTIVE STUDIES; PYODERMA GANGRENOSUM; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME;

EID: 52249087339     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2008.02680.x     Document Type: Article

References (27)

1. Wines N, Wines M, Ryman W. Understanding pyoderma gangrenosum: a review. Medscape June 2001.
2. Bennett UL, Jackson JM, Jorizzo JL, Fleischer AB Jr., White WL, Callen JP. Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine (Baltimore) 2000 79 : 37 46.
3. Crowson AN, Mihm MC, Magro C. Pyoderma gangrenosum: a review. J Cutan Pathol 2003 30 : 97 107.
4. Chow RKP, Ho VC. Treatment of pyoderma gangrenosum. J Am Acad Derm 1996 34 : 1047 1060.
5. Reichrath J, Bens G, Bonowitz A, Tilgen W. Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol 2005 53 : 273 283.
6. Brottier P, Boumsell L, Gelin C, Bernard A. T cell activation via CD2 (T11, gp50) molecules: accessory cells are required to trigger T cell activation via CD2 D66 plus CD2-9.6/T11(1): epitopes. J Immunol 1985 135 : 1624.
7. Meuer SC, Hussey RE, Fabbi M et al. An alternative pathway of T cell activation: a functional role for the 50 KD T11 sheep erythrocyte receptor protein. Cell 1984 36 : 897.
8. Alcover A, Alberini C, Acuto LK et al. Interdependence of CD3-Ti and CD2 activation pathways in human T lymphocytes. Embo J 1988 7 : 1973.
9. June CH, Fletcher MC, Ledbetter JA, Samelson LE. Increase in tyrosine phosphorylation are detectable before phospholipase C activation after T cell receptor stimulation. J Immunol 1990 144 : 1591.
10. Ley SC, Davies AA, Druker B, Crumpton MJ. The T cell receptor/CD3 complex and CD2 stimulate the tyrosine phosphorylation of indistinguishable patterns of polypeptides in the human T-leukemic cell line Jurkat. Eur J Immunol 1991 21 : 2203.
11. Danielian S, Fagard SR, Alcover A, Acuto O, Fischer S. The tyrosine kinase activity of p56 lck is increased in human T cells activated via CD2. Eur J Immunol 1991 21 : 1967.
12. Kanner SB, DaμLe NK, Blake J, Aruffo A, Ledbetter JA. CD2/LFA-3 ligation induces phospholipase-C gamma tyrosine phosphorylation and regulates CD3 signaling. J Immunol 1992 148 : 2023.
13. Dustin UL, Selvaraj P, Mattaliano RJ, Springer TA. Anchoring mechanisms for LFA-3 cell adhesion glycoprotein at membrane surface. Nature 1987 329 : 846.
14. Seed B. An LFA-3 cDNA encodes a phospholipid-linked membrane protein homologous to its receptor CD2. Nature 1987 329 : 840.
15. Wallner BP, Frey AZ, Tizard R et al. Primary structure of lymphocyte function-associated antigen 3 (LFA-3). The ligand of the T lymphocyte CD2 glycoprotein. J Exp Med 1987 166 : 923.
16. Schraven B, Wild M, Kirchgessner H et al. Alterations of CD2 association of T cell receptor signaling molecules in 'CD2 unresponsive' human T lymphocytes. Eur J Immunol 1993 23 : 119 123.
17. Webb DS, Shimizu Y, Van Seventer G, Shaw S, Gerrard TL. LFA-3, CD44, and CD45: physiologic triggers of human monocyte TNF and IL-1 release. Science 1990 249 : 1295.
18. Sanders ME, Makgoba MW, Sharrow SO et al. Human memory T lymphocytes express increased levels of three cell adhesion molecules (LFA-3, CD2, and LFA-1) and three other molecules (UCHL1, CDw29, and Pgp-1) and have enhanced IFN-gamma production. J Immunol 1988 140 : 1401.
19. Moingeon P, Chang HC, Wallner BP, Stebbins C, Frey AZ, Reinherz EL. CD2-mediated adhesion facilitates T lymphocyte antigen recognition function. Nature 1989 339 : 312.
20. Holt PJ, Davies MG, Saunders KC, Nuki G. Pyoderma gangrenosum. clinical and laboratory findings in 15 patients with special reference to polyarthritis. Medicine (Baltimore) 1980 59 : 114 133.
21. Schofer H, Baur S. Successful treatment of postoperative pyoderma gangrenosum with cyclosporine. JEADV 2002 16 : 148 151.
22. Hagman JH, Carrozzo AM, Campione E, Romanelli P, Chimenti S. The use of high-dose immunoglobulin in the treatment of pyoderma gangrenosum. J Dermat Treatment 2001 12 : 19 22.
23. Perri AJ, Hsu S. A review of thalidomide's history and current dermatological applications. Dermatol Online J 9 : 5.
24. Reguerio M, Valentine J, Plevy S, Fleisher MR, Lichtenstein GR. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory Bowel disease. Am J Gastroenterol 2003 98 : 1821 1826.
25. Mimouni D, Anhalt GJ, Kouba DJ, Nousari HC. Infliximab for peristomal pyoderma gangrenosum. 2003 148 : 813 816.
26. Tam M, Gordon M, Lebwohl O, George J, Lebwohl MG. Improvement of pyodera gangrenosum and psoriasis associated with Crohn Disease with anti-tumor necrosis factor α monoclonal antibody. Arch Dermatol 2001 137 : 930 933.
27. Brooklyn TN, Dunnill MGS, Shetty A et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 2006 55 : 505 509.